Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA

Prolia^®: In patients with postmenopausal osteoporosis, the most frequently reported adverse reactions included back musculoskeletal and extremity pain …
Source: back pain